Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 1

Interventions

Adalimumab 19Etanercept 16Methotrexate 11Infliximab 8tocilizumab 7Rituximab 7golimumab 6Abatacept 6tofacitinib 5Tumor Necrosis Factor Inhibitors 5olokizumab 4Certolizumab Pegol 4Antirheumatic Agents 3Saline Solution 2RC-18 2Nivolumab 2Leflunomide 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1entecavir 1cabozantinib 1baricitinib 1andecaliximab 1Vitamin D 1Vaccines 1TACI receptor-IgG Fc fragment fusion protein 1Syringes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Arthritis, Rheumatoid × ISIS104838 × Clear all
NCT00048321 2022-12-05

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

Ionis Pharmaceuticals, Inc.

Phase 2 Completed
160 enrolled

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡